|Day Low/High||76.20 / 77.53|
|52 Wk Low/High||60.89 / 85.97|
The problem for index fund owners is they own all three buckets and there are a lot more companies in the third bucket than in the first two.
It was another day in which there was some bad news out of Gilead and the bad economic data continues. From my perch, Mr. Market is doing a good job of consolidating a spectacular gain from the mid-March bottom. * Oil +$3.20/barrel. (And energy stoc...
In Twitter feeds I can feel the Bears rooting for the markets to go down. (While anything can happen) I am not so sure it's going to happen today - even with the Gilead news. I will end the day longer than I started the day.
Brains per share. Hearts Per Share. I've been around long enough to be that positive. I like these companies and more importantly, I like their stocks.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
Will tech continue to trend toward leadership? Who among us can remember when it has not?
More than 450 quarterly reports are on tap, including 105 S&P 500 constituents.
Long-term investors must buy during bear markets -- and these companies offer dividend reinvestment or direct investment plans to help seize the opportunity.
I have to believe that a few more weeks of lower oil prices and we will see more bankruptcy filings.
Today is about hope on two fronts: the markets and society.
I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.
* For investment and placing stock on my Best Ideas List I'll get into the tactical moves I made last night (after the S&P futures rose by nearly +90 handles in response to the Gilead Sciences drug news), but I wanted to mention that I am shorting A...
From early last night - I sold down my position based on "The Smartest Trader" comments that the rise in gold was looking "tired", the reduced reward vs. risk (short term), and because of the positive equity impact on the Gilead drug announcement (a...
There is likely to be some period of consolidation as market players assess the many crosscurrents that are occurring.
The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.
Friday is the April expiration for S&P 500 index options -- and that can explain more or less why the market has been so tightly pinned.
How has my book evolved since the Fed and Treasury rode into town? Here's how.
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.
As testing expands, drug trials proceed and tech greats are providing a tracking app, I think we're inching toward going back to work -- and further away from going so low again.
I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.
Trading action has been jumpy, so where's the trend?
Over the past month, 3 sectors have revealed themselves as market leaders: Technology, Healthcare and Consumer Staples.
The presidential task force wasn't going to address the media Sunday. Then, they did. Actual news? Futures markets opened ahead of that, in the green, and went higher. That's interesting.
For March and the first quarter, the RMPIA takes less of a hit than major indexes.
The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.